IN2012DN04940A - - Google Patents

Download PDF

Info

Publication number: IN2012DN04940A
Authority: IN; India
Prior art keywords: disclosed; hif; immune response; inducible factor; hypoxia inducible
Prior art date: 2009-11-06

Application number

Other languages

English (en)

Inventor

Joseph H Gardner

Robert Shalwitz

Original Assignee

Aerpio Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-11-06

Filing date

2010-11-05

Publication date

2015-09-25

2010-11-05 Application filed by Aerpio Therapeutics Inc filed Critical Aerpio Therapeutics Inc

2015-09-25 Publication of IN2012DN04940A publication Critical patent/IN2012DN04940A/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Immunology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Virology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Obesity (AREA)
Pulmonology (AREA)
Emergency Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyridine Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

IN4940DEN2012 2009-11-06 2010-11-05 IN2012DN04940A (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US25891409P	2009-11-06	2009-11-06
US25891809P	2009-11-06	2009-11-06
PCT/US2010/055694 WO2011057115A1 (fr)	2009-11-06	2010-11-05	Inhibiteurs de prolyl hydrolase

Publications (1)

Publication Number	Publication Date
IN2012DN04940A true IN2012DN04940A (fr)	2015-09-25

Family

ID=43970365

Family Applications (3)

Application Number	Title	Priority Date
IN4949DEN2012 IN2012DN04949A (fr)	2009-11-06	2010-11-05
IN4950DEN2012 IN2012DN04950A (fr)	2009-11-06	2010-11-05
IN4940DEN2012 IN2012DN04940A (fr)	2009-11-06	2010-11-05

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
IN4949DEN2012 IN2012DN04949A (fr)	2009-11-06	2010-11-05
IN4950DEN2012 IN2012DN04950A (fr)	2009-11-06	2010-11-05

Country Status (28)

Country	Link
US (11)	US8778412B2 (fr)
EP (9)	EP2649998B1 (fr)
JP (6)	JP5591939B2 (fr)
KR (8)	KR101591701B1 (fr)
CN (3)	CN102612367B (fr)
AU (3)	AU2010314976B2 (fr)
BR (3)	BR112012010759B1 (fr)
CA (3)	CA2774039A1 (fr)
DK (4)	DK2853265T3 (fr)
ES (5)	ES2424122T3 (fr)
HK (1)	HK1208806A1 (fr)
HR (3)	HRP20130691T1 (fr)
HU (1)	HUE026109T2 (fr)
IL (4)	IL219612A (fr)
IN (3)	IN2012DN04949A (fr)
MX (4)	MX2012005275A (fr)
MY (3)	MY160066A (fr)
NO (1)	NO2853265T3 (fr)
NZ (4)	NZ600396A (fr)
PH (3)	PH12012500790A1 (fr)
PL (4)	PL2496236T4 (fr)
PT (4)	PT2853265T (fr)
RS (3)	RS54124B1 (fr)
RU (3)	RU2518071C2 (fr)
SI (2)	SI2496084T1 (fr)
SM (1)	SMT201300096B (fr)
WO (3)	WO2011057121A1 (fr)
ZA (1)	ZA201204104B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2007237096C1 (en)	2006-04-07	2012-12-13	EyePoint Pharmaceuticals, Inc.	Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
US7622593B2 (en)	2006-06-27	2009-11-24	The Procter & Gamble Company	Human protein tyrosine phosphatase inhibitors and methods of use
CN105412094A (zh)	2009-07-06	2016-03-23	爱尔皮奥治疗有限公司	用于防止癌细胞转移的化合物、组合物和方法
US9205129B2 (en) *	2009-10-09	2015-12-08	University Of Rochester	Methods of treatment and screening assays for HIF-1α regulation
ES2424122T3 (es) *	2009-11-06	2013-09-27	Aerpio Therapeutics Inc.	Inhibidores de la prolilhidroxilasa
NO2686520T3 (fr)	2011-06-06	2018-03-17
CA2837560C (fr) *	2011-06-06	2017-02-14	Akebia Therapeutics Inc.	Composes et compositions pour la stabilisation du facteur 2 alpha inductible par l'hypoxie comme procede de traitement du cancer
US20130095065A1 (en)	2011-10-13	2013-04-18	Aerpio Therapeutics, Inc.	Methods for Treating Vascular Leak Syndrome and Cancer
WO2014145331A1 (fr) *	2013-03-15	2014-09-18	University Of Southern California	Procédés, composés et compositions pour le traitement de maladies liées à l'angiotensine
HK1206558A1 (en)	2013-03-15	2016-01-15	Aerpio Therapeutics Inc	Compositions, formulations and methods for treating ocular diseases
US20150050277A1 (en)	2013-03-15	2015-02-19	Aerpio Therapeutics Inc.	Compositions and methods for treating ocular diseases
HRP20240319T1 (hr)	2013-06-13	2024-05-24	Akebia Therapeutics, Inc.	Pripravci i postupci za liječenje anemije
CN106232120B (zh) *	2014-02-19	2021-01-08	爱尔皮奥治疗有限公司	制备n-苄基-3-羟基-4-取代的-吡啶-2-(1h)-酮的方法
EP3116503A4 (fr)	2014-03-14	2017-08-23	Aerpio Therapeutics, Inc.	Inhibiteurs de hptp-bêta
WO2016022813A1 (fr)	2014-08-07	2016-02-11	Aerpio Therapeutics, Inc.	Combinaison d'immunothérapies avec des activateurs de tie -2
HK1247201A1 (zh)	2015-01-23	2018-09-21	阿克比治疗有限公司	2-(5-(3-氟苯基)-3-羟基吡啶甲醯胺)乙酸的固体形式、其组合物及用途
SI3277270T1 (sl)	2015-04-01	2022-04-29	Akebia Therapeutics, Inc.	Sestavki in postopki za zdravljenje anemije
WO2019100053A1 (fr)	2017-11-20	2019-05-23	University Of Georgia Research Foundation, Inc.	Compositions et procédés pour moduler hif-2a afin d'améliorer la production et la réparation des muscles
CA3097219A1 (fr)	2018-05-09	2019-11-14	Akebia Therapeutics, Inc.	Procede de preparation d'acide 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino]acetique
JP7695187B2 (ja)	2018-09-24	2025-06-18	アイポイントファーマシューティカルズ，インコーポレイテッド	ＨＰＴＰ－β（ＶＥ－ＰＴＰ）およびＶＥＧＦを標的にする多特異性抗体
CN114980898A (zh) *	2019-11-20	2022-08-30	安吉昂生物医药公司	用于治疗炎性肠病的方法
WO2021119033A1 (fr) *	2019-12-09	2021-06-17	Gb004, Inc.	Compositions et méthodes de traitement
CA3169000A1 (fr) *	2020-03-11	2021-09-16	Hideki Takeuchi	Cristal d'un compose d'imidazopyridinone ou d'un sel de celui-ci
WO2022036267A1 (fr) *	2020-08-13	2022-02-17	Gb004, Inc.	Compositions et méthodes de traitement
WO2022036269A1 (fr) *	2020-08-13	2022-02-17	Gb004, Inc.	FORMES CRISTALLINES D'UN INHIBITEUR HIF-1α PROLYL HYDROXYLASE
MX2023009060A (es) *	2021-02-02	2023-09-29	Liminal Biosciences Ltd	Antagonistas de gpr84 y usos de estos.
CA3206499A1 (fr)	2021-02-02	2022-08-11	Liminal Biosciences Limited	Antagonistes du gpr84 et leurs utilisations
KR102507532B1 (ko) *	2022-09-14	2023-03-10	주식회사 에이치디에스바이오	락토바실러스 플란타룸 hac03 균주 및 플라보노이드를 포함하는 염증성 장질환 예방 또는 치료용 조성물
WO2024165507A1 (fr) *	2023-02-06	2024-08-15	Institut National de la Santé et de la Recherche Médicale	Utilisation d'agents de stabilisation de hif-1a pour le traitement d'interféronopathies de type i
CN116196314B (zh) *	2023-05-04	2023-08-15	广州市妇女儿童医疗中心	Ri-1或其盐在制备防治胃肠道疾病的药物中的应用

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3710795A (en)	1970-09-29	1973-01-16	Alza Corp	Drug-delivery device with stretched, rate-controlling membrane
US3894920A (en) *	1971-12-21	1975-07-15	Sagami Chem Res	Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US3853900A (en) *	1973-09-14	1974-12-10	Searle & Co	4-benzyloxy-2 (1h)-pyridones
US5358949A (en) *	1986-03-05	1994-10-25	Otsuka Pharmaceutical Co., Ltd.	Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
TW219933B (fr)	1990-02-26	1994-02-01	Lilly Co Eli
DE4221583A1 (de) *	1991-11-12	1993-05-13	Bayer Ag	Substituierte biphenylpyridone
DE4316077A1 (de) *	1993-05-13	1994-11-17	Bayer Ag	Substituierte Mono- und Bihydridylmethylpyridone
DE59401923D1 (de) *	1993-11-02	1997-04-10	Hoechst Ag	Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
NZ270267A (en) *	1993-12-30	1997-03-24	Hoechst Ag	3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
US6046219A (en) *	1995-01-20	2000-04-04	Cornell Research Foundation, Inc.	Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation
US5789426A (en) *	1995-01-20	1998-08-04	Cornell Research Foundation, Inc.	Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
US5849587A (en) *	1995-06-09	1998-12-15	Cornell Research Foundation, Inc.	Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells
KR20000065090A (ko)	1996-04-30	2000-11-06	훽스트 악티엔게젤샤프트	3-알콕시피리딘-2-카복실산아미드에스테르,이의제조방법및약제로서의이의용도
DE19650215A1 (de) *	1996-12-04	1998-06-10	Hoechst Ag	3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
UA66370C2 (en) *	1997-12-16	2004-05-17	Lilly Co Eli	Arylpiperazines having activity to setotonin 1 receptors
US6589758B1 (en)	2000-05-19	2003-07-08	Amgen Inc.	Crystal of a kinase-ligand complex and methods of use
CA2433158C (fr)	2000-12-28	2011-05-10	Shionogi & Co., Ltd.	Derive de pyridone comportant une activite de liaison a un recepteur cannabinoide de type 2
US6849718B2 (en)	2001-03-20	2005-02-01	Dana Farber Cancer Institute, Inc.	Muteins of hypoxia inducible factor alpha and methods of use thereof
US6855510B2 (en) *	2001-03-20	2005-02-15	Dana Farber Cancer Institute, Inc.	Pharmaceuticals and methods for treating hypoxia and screening methods therefor
EP1379630B1 (fr)	2001-03-21	2012-09-26	Isis Innovation Limited	Procedes, methodes et dispositifs concernant l'hydroxylase de l'hif
US6566088B1 (en)	2001-10-04	2003-05-20	Board Of Regents, The University Of Texas System	Prolyl-4-hydroxylases
CN100522946C (zh) *	2001-12-06	2009-08-05	法布罗根股份有限公司	低氧诱导因子(HIF)α的稳定化
BR0307157A (pt)	2002-01-11	2004-12-07	Rhodianyl	Uso do sulfeto de zino, composição com propriedade antiácaros, fios, fibras e filamentos, artigos e artigo têxtil
US7226755B1 (en)	2002-09-25	2007-06-05	The Procter & Gamble Company	HPTPbeta as a target in treatment of angiogenesis mediated disorders
US7507568B2 (en)	2002-09-25	2009-03-24	The Proctor & Gamble Company	Three dimensional coordinates of HPTPbeta
MXPA05004033A (es)	2002-10-16	2005-06-08	Isis Innovation	Hidroxilasas de asparaginil y moduladores de las mismas.
US6946479B2 (en)	2002-11-09	2005-09-20	The Procter & Gamble Company	N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones
US6930117B2 (en) *	2002-11-09	2005-08-16	The Procter & Gamble Company	N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
CA2517888C (fr) *	2003-03-14	2012-05-01	Ono Pharmaceutical Co., Ltd.	Derives heterocycliques renfermant de l'azote et medicaments contenant ces derives comme principe actif
US7183287B2 (en)	2003-04-03	2007-02-27	Pharmacia Corporation	Substituted pyrimidinones
CN103145616B (zh) *	2003-06-06	2015-09-30	菲布罗根有限公司	含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
WO2005007192A2 (fr)	2003-06-06	2005-01-27	Fibrogen, Inc.	Cytoprotection
JP2007503435A (ja) *	2003-08-26	2007-02-22	ベクトン・ディキンソン・アンド・カンパニー	治療薬の皮内送達法
AU2004285351A1 (en) *	2003-10-31	2005-05-12	Earth Chemical Co., Ltd.	Material in gel state
WO2005051933A1 (fr) *	2003-11-28	2005-06-09	Ranbaxy Laboratories Limited	Procede ameliore de synthese d'ester test-butylique d'acide 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-1-carboxylique, compose intermediaire cle de la preparation d'agents antimicrobiens a l'oxazolidinone, et composes ainsi prepares
EP1713773A4 (fr)	2004-01-30	2009-09-23	Merck & Co Inc	Composes de n-benzyl-3,4-dihyroxypyridine-2-carboxamide et de n-benzyl-2,3-dihydroxypyridine-4-carboxamide, utiles en tant qu'inhibiteurs de l'integrase du vih
US20050258126A1 (en)	2004-05-21	2005-11-24	Aniceto Canamasas Puigbo	Double bottomed jar
ES2332798T3 (es)	2004-05-28	2010-02-12	Fibrogen, Inc.	Ensayo de actividad de la prolil hidroxilasa de hif.
US7718624B2 (en) *	2004-09-01	2010-05-18	Sitkovsky Michail V	Modulation of immune response and inflammation by targeting hypoxia inducible factors
WO2006084210A2 (fr)	2005-02-04	2006-08-10	Regents Of The University Of California, San Diego	Composes modulant le hif et methodes d'utilisation associees
US7588824B2 (en) *	2005-02-25	2009-09-15	The Regents Of The University Of California	Hydrogen cyano fullerene containing proton conducting membranes
CA2603926A1 (fr) *	2005-04-08	2006-10-12	Neuromed Pharmaceuticals Ltd.	Therapie de combinaison qui comprend un agent bloquant les canaux calciques de type n pour le soulagement de la douleur
US8177417B2 (en) *	2005-04-25	2012-05-15	Harsco Technologies Corporation	Apparatus for continuous blending
DE102005019712A1 (de)	2005-04-28	2006-11-09	Bayer Healthcare Ag	Dipyridyl-dihydropyrazolone und ihre Verwendung
JP5390184B2 (ja) *	2005-06-06	2014-01-15	ファイブローゲン、インコーポレーテッド	貧血の改良された治療方法
WO2007033216A2 (fr) *	2005-09-12	2007-03-22	Beth Israel Deaconess Medical Center	Procedes et compositions pour le traitement et le diagnostic de maladies caracterisees par la fuite vasculaire, l'hypotension, ou un etat procoagulant
WO2007038571A2 (fr)	2005-09-26	2007-04-05	Smithkline Beecham Corporation	Antagonistes de la prolyl-hydroxylase
US20090176726A1 (en)	2005-10-11	2009-07-09	Fisher David E	Methods for treating mitf-related disorders
US7728130B2 (en)	2005-12-09	2010-06-01	Amgen Inc.	Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity
WO2007082899A1 (fr)	2006-01-17	2007-07-26	Vib Vzw	Inhibiteurs de la prolyl-hydroxylase 1 pour le traitement de la degenerescence des muscles du squelette
US7588924B2 (en)	2006-03-07	2009-09-15	Procter & Gamble Company	Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
PE20071020A1 (es)	2006-03-07	2007-12-11	Smithkline Beecham Corp	Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa
US8968702B2 (en)	2006-03-30	2015-03-03	Duke University	Inhibition of HIF-1 activation for anti-tumor and anti-inflammatory responses
AU2007237096C1 (en)	2006-04-07	2012-12-13	EyePoint Pharmaceuticals, Inc.	Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
JP2009537558A (ja)	2006-05-16	2009-10-29	スミスクライン・ビーチャム・コーポレイション	プロリルヒドロキシラーゼ阻害剤
TWI394747B (zh)	2006-06-23	2013-05-01	Smithkline Beecham Corp	脯胺醯基羥化酶抑制劑
EP2044005B8 (fr) *	2006-06-26	2012-12-05	Warner Chilcott Company, LLC	Inhibiteurs de la prolyl hydroxylase et procédés d'utilisation
US7795444B2 (en)	2006-06-27	2010-09-14	Warner Chilcott Company	Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en)	2006-06-27	2014-09-30	Aerpio Therapeutics Inc.	Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en)	2006-06-27	2009-11-24	The Procter & Gamble Company	Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en)	2006-06-27	2009-09-15	Procter & Gamble Company	Human protein tyrosine phosphatase inhibitors and methods of use
US20130023542A1 (en)	2006-06-27	2013-01-24	Aerpio Therapeutics Inc.	Human protein tyrosine phosphatase inhibitors and methods of use
JP5265381B2 (ja)	2006-12-07	2013-08-14	テルモ株式会社	輸液チューブセット
US7635715B2 (en) *	2006-12-18	2009-12-22	Amgen Inc.	Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
CL2008000065A1 (es)	2007-01-12	2008-09-22	Smithkline Beecham Corp	Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia.
TW200845991A (en)	2007-01-12	2008-12-01	Smithkline Beecham Corp	N-substituted glycine derivatives: hydroxylase inhibitors
ES2446418T3 (es)	2007-04-18	2014-03-07	Amgen, Inc	Derivados de indanona que inhiben la prolil hidroxilasa
WO2008130527A1 (fr)	2007-04-18	2008-10-30	Merck & Co., Inc.	Nouveaux composés de type 1,8-naphthyridine
EP2150251B9 (fr)	2007-05-04	2013-02-27	Amgen, Inc	Derives de la thienopyridine et de la thiazolopyridine qui inhibent l'activite prolyle hydroxylase
CA2685942A1 (fr)	2007-05-16	2008-11-27	Merck & Co., Inc.	Spiroindalones
TW200908984A (en)	2007-08-07	2009-03-01	Piramal Life Sciences Ltd	Pyridyl derivatives, their preparation and use
US20110028507A1 (en)	2007-08-10	2011-02-03	Crystalgenomics, Inc.	Pyridine derivatives and methods of use thereof
WO2009039323A1 (fr)	2007-09-19	2009-03-26	Smithkline Beecham Corporation	Inhibiteurs de la prolyl hydroxylase
WO2009039321A1 (fr)	2007-09-19	2009-03-26	Smithkline Beecham Corporation	Inhibiteurs de la prolyl hydroxylase
WO2009043093A1 (fr)	2007-10-04	2009-04-09	Newsouth Innovations Pty Limited	Inhibition de hif
WO2009049112A1 (fr)	2007-10-10	2009-04-16	Smithkline Beecham Corporation	Inhibiteurs de la prolyl hydroxylase
FR2924205B1 (fr)	2007-11-23	2013-08-16	Air Liquide	Dispositif et procede de refrigeration cryogenique
WO2009067790A1 (fr)	2007-11-26	2009-06-04	Uti Limited Partnership	STIMULATION DU FACTEUR 1α INDUCTIBLE PAR L'HYPOXIE (HIF-1α) POUR LE TRAITEMENT DE LA MALADIE ASSOCIÉE À CLOSTRIDIUM DIFFICILE (MACD), POUR LA MOTILITÉ INTESTINALE ET POUR DÉTECTER UNE INFECTION
CN101932324A (zh)	2007-11-30	2010-12-29	葛兰素史密斯克莱有限责任公司	脯氨酰羟化酶抑制剂
WO2009073497A2 (fr)	2007-11-30	2009-06-11	Smithkline Beecham Corporation	Inhibiteurs des prolyl hydroxylases
WO2009073669A1 (fr)	2007-12-03	2009-06-11	Fibrogen, Inc.	Dérivés d'isoxazolopyridine destinés à être utilisés dans le traitement d'états à médiation par hif
US8323952B2 (en)	2007-12-13	2012-12-04	Archer Daniels Midland Company	Alcoholic xylose fermentation at high temperatures by the thermotolerant yeast Hansenula polymorpha
EP2240178A4 (fr)	2007-12-19	2011-10-26	Glaxosmithkline Llc	Inhibiteurs de prolylhydroxylase
WO2009086592A1 (fr)	2008-01-04	2009-07-16	Garvan Institute Of Medical Research	Procédé d'augmentation du métabolisme
US8952160B2 (en)	2008-01-11	2015-02-10	Fibrogen, Inc.	Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
SG172312A1 (en)	2009-01-12	2011-07-28	Akebia Therapeutics Inc	Methods for treating vascular leak syndrome
US9096555B2 (en)	2009-01-12	2015-08-04	Aerpio Therapeutics, Inc.	Methods for treating vascular leak syndrome
CN105412094A (zh)	2009-07-06	2016-03-23	爱尔皮奥治疗有限公司	用于防止癌细胞转移的化合物、组合物和方法
US8883832B2 (en)	2009-07-06	2014-11-11	Aerpio Therapeutics Inc.	Compounds, compositions, and methods for preventing metastasis of cancer cells
ES2424122T3 (es) *	2009-11-06	2013-09-27	Aerpio Therapeutics Inc.	Inhibidores de la prolilhidroxilasa
NZ610230A (en)	2010-10-07	2015-07-31	Aerpio Therapeutics Inc	Compositions and methods for treating ocular edema, neovascularization and related diseases
CA2837560C (fr)	2011-06-06	2017-02-14	Akebia Therapeutics Inc.	Composes et compositions pour la stabilisation du facteur 2 alpha inductible par l'hypoxie comme procede de traitement du cancer
CN107080843A (zh)	2011-10-13	2017-08-22	爱尔皮奥治疗有限公司	眼病的治疗
US20130095065A1 (en)	2011-10-13	2013-04-18	Aerpio Therapeutics, Inc.	Methods for Treating Vascular Leak Syndrome and Cancer
HK1206558A1 (en)	2013-03-15	2016-01-15	Aerpio Therapeutics Inc	Compositions, formulations and methods for treating ocular diseases
US20150050277A1 (en)	2013-03-15	2015-02-19	Aerpio Therapeutics Inc.	Compositions and methods for treating ocular diseases
CN106232120B (zh)	2014-02-19	2021-01-08	爱尔皮奥治疗有限公司	制备n-苄基-3-羟基-4-取代的-吡啶-2-(1h)-酮的方法
US9884456B2 (en)	2014-02-24	2018-02-06	Ethicon Llc	Implantable layers and methods for altering one or more properties of implantable layers for use with fastening instruments

2010
- 2010-11-05 ES ES10829176T patent/ES2424122T3/es active Active
- 2010-11-05 NO NO14193060A patent/NO2853265T3/no unknown
- 2010-11-05 DK DK14193060.2T patent/DK2853265T3/da active
- 2010-11-05 BR BR112012010759-3A patent/BR112012010759B1/pt not_active IP Right Cessation
- 2010-11-05 RS RS20150485A patent/RS54124B1/sr unknown
- 2010-11-05 IN IN4949DEN2012 patent/IN2012DN04949A/en unknown
- 2010-11-05 PH PH1/2012/500790A patent/PH12012500790A1/en unknown
- 2010-11-05 KR KR1020157026346A patent/KR101591701B1/ko not_active Expired - Fee Related
- 2010-11-05 SI SI201030987T patent/SI2496084T1/sl unknown
- 2010-11-05 ES ES15164257T patent/ES2782999T3/es active Active
- 2010-11-05 MX MX2012005275A patent/MX2012005275A/es active IP Right Grant
- 2010-11-05 MX MX2012005273A patent/MX2012005273A/es not_active Application Discontinuation
- 2010-11-05 KR KR1020147026829A patent/KR20140122283A/ko not_active Withdrawn
- 2010-11-05 AU AU2010314976A patent/AU2010314976B2/en not_active Ceased
- 2010-11-05 EP EP13165749.6A patent/EP2649998B1/fr not_active Not-in-force
- 2010-11-05 RS RS20130321A patent/RS52870B/sr unknown
- 2010-11-05 DK DK10829180.8T patent/DK2496084T3/en active
- 2010-11-05 RU RU2012123387/04A patent/RU2518071C2/ru not_active IP Right Cessation
- 2010-11-05 ES ES10829180.8T patent/ES2541613T3/es active Active
- 2010-11-05 DK DK13165749.6T patent/DK2649998T3/en active
- 2010-11-05 CA CA2774039A patent/CA2774039A1/fr not_active Abandoned
- 2010-11-05 ES ES14193060.2T patent/ES2644998T3/es active Active
- 2010-11-05 NZ NZ600396A patent/NZ600396A/en not_active IP Right Cessation
- 2010-11-05 BR BR112012010766A patent/BR112012010766A2/pt not_active Application Discontinuation
- 2010-11-05 MY MYPI2012001216A patent/MY160066A/en unknown
- 2010-11-05 MX MX2012005274A patent/MX2012005274A/es active IP Right Grant
- 2010-11-05 PL PL10829176T patent/PL2496236T4/pl unknown
- 2010-11-05 AU AU2010314973A patent/AU2010314973B9/en not_active Ceased
- 2010-11-05 KR KR1020127014419A patent/KR101445946B1/ko not_active Expired - Fee Related
- 2010-11-05 PL PL14193060T patent/PL2853265T3/pl unknown
- 2010-11-05 JP JP2012537240A patent/JP5591939B2/ja not_active Expired - Fee Related
- 2010-11-05 EP EP10829180.8A patent/EP2496084B1/fr active Active
- 2010-11-05 WO PCT/US2010/055704 patent/WO2011057121A1/fr not_active Ceased
- 2010-11-05 RU RU2012123388/15A patent/RU2518416C2/ru not_active IP Right Cessation
- 2010-11-05 PH PH1/2012/500789A patent/PH12012500789A1/en unknown
- 2010-11-05 DK DK10829176.6T patent/DK2496236T3/da active
- 2010-11-05 CN CN201080050181.9A patent/CN102612367B/zh not_active Expired - Fee Related
- 2010-11-05 PT PT141930602T patent/PT2853265T/pt unknown
- 2010-11-05 PT PT108291766T patent/PT2496236E/pt unknown
- 2010-11-05 NZ NZ629733A patent/NZ629733A/en not_active IP Right Cessation
- 2010-11-05 SI SI201030927T patent/SI2649998T1/sl unknown
- 2010-11-05 JP JP2012537237A patent/JP5599467B2/ja not_active Expired - Fee Related
- 2010-11-05 CA CA2774046A patent/CA2774046C/fr not_active Expired - Fee Related
- 2010-11-05 BR BR112012010762-3A patent/BR112012010762B1/pt not_active IP Right Cessation
- 2010-11-05 NZ NZ600405A patent/NZ600405A/en not_active IP Right Cessation
- 2010-11-05 US US12/940,883 patent/US8778412B2/en active Active
- 2010-11-05 KR KR1020147017414A patent/KR20140095105A/ko not_active Abandoned
- 2010-11-05 US US12/940,891 patent/US8536181B2/en not_active Expired - Fee Related
- 2010-11-05 EP EP10829176.6A patent/EP2496236B1/fr active Active
- 2010-11-05 MY MYPI2012001219A patent/MY161880A/en unknown
- 2010-11-05 KR KR1020127014454A patent/KR101483831B1/ko not_active Expired - Fee Related
- 2010-11-05 EP EP19174520.7A patent/EP3603644A1/fr not_active Withdrawn
- 2010-11-05 JP JP2012537236A patent/JP5627040B2/ja not_active Expired - Fee Related
- 2010-11-05 PH PH1/2012/500788A patent/PH12012500788A1/en unknown
- 2010-11-05 PL PL10829180T patent/PL2496084T3/pl unknown
- 2010-11-05 MY MYPI2012001217A patent/MY163511A/en unknown
- 2010-11-05 KR KR1020157001507A patent/KR101613103B1/ko not_active Expired - Fee Related
- 2010-11-05 AU AU2010314982A patent/AU2010314982B2/en not_active Ceased
- 2010-11-05 CN CN201080050210.1A patent/CN102595896B/zh not_active Expired - Fee Related
- 2010-11-05 EP EP15154363.4A patent/EP2952192B1/fr not_active Not-in-force
- 2010-11-05 KR KR1020147008577A patent/KR20140048341A/ko not_active Ceased
- 2010-11-05 WO PCT/US2010/055694 patent/WO2011057115A1/fr not_active Ceased
- 2010-11-05 MX MX2013009454A patent/MX365138B/es unknown
- 2010-11-05 CA CA2774043A patent/CA2774043C/fr not_active Expired - Fee Related
- 2010-11-05 EP EP20150482.6A patent/EP3698794A1/fr not_active Withdrawn
- 2010-11-05 IN IN4950DEN2012 patent/IN2012DN04950A/en unknown
- 2010-11-05 NZ NZ600400A patent/NZ600400A/en not_active IP Right Cessation
- 2010-11-05 HR HRP20130691AT patent/HRP20130691T1/hr unknown
- 2010-11-05 EP EP15164257.6A patent/EP2954899B1/fr active Active
- 2010-11-05 PT PT108291808T patent/PT2496084E/pt unknown
- 2010-11-05 KR KR1020127014522A patent/KR20120088833A/ko not_active Ceased
- 2010-11-05 CN CN201080050212.0A patent/CN102638983B/zh not_active Expired - Fee Related
- 2010-11-05 EP EP14193060.2A patent/EP2853265B1/fr not_active Not-in-force
- 2010-11-05 RS RS20150173A patent/RS54010B1/sr unknown
- 2010-11-05 PL PL13165749T patent/PL2649998T3/pl unknown
- 2010-11-05 ES ES13165749.6T patent/ES2533128T3/es active Active
- 2010-11-05 WO PCT/US2010/055691 patent/WO2011057112A1/fr not_active Ceased
- 2010-11-05 US US12/940,901 patent/US8309537B2/en not_active Expired - Fee Related
- 2010-11-05 RU RU2012123386/15A patent/RU2521251C2/ru not_active IP Right Cessation
- 2010-11-05 HU HUE10829180A patent/HUE026109T2/en unknown
- 2010-11-05 PT PT131657496T patent/PT2649998E/pt unknown
- 2010-11-05 IN IN4940DEN2012 patent/IN2012DN04940A/en unknown
- 2010-11-05 EP EP10829174.1A patent/EP2496082B1/fr not_active Not-in-force
- 2010-11-05 HR HRP20150772TT patent/HRP20150772T1/hr unknown
2012
- 2012-05-06 IL IL219612A patent/IL219612A/en active IP Right Grant
- 2012-05-06 IL IL219610A patent/IL219610A/en active IP Right Grant
- 2012-05-06 IL IL219611A patent/IL219611A/en not_active IP Right Cessation
- 2012-06-05 ZA ZA2012/04104A patent/ZA201204104B/en unknown
2013
- 2013-02-15 US US13/768,308 patent/US9045495B2/en not_active Expired - Fee Related
- 2013-02-19 US US13/770,135 patent/US8883774B2/en active Active
- 2013-09-05 SM SM201300096T patent/SMT201300096B/xx unknown
2014
- 2014-03-07 JP JP2014045734A patent/JP2014139206A/ja not_active Withdrawn
- 2014-03-07 JP JP2014045733A patent/JP5865411B2/ja not_active Expired - Fee Related
- 2014-07-30 JP JP2014155145A patent/JP5961665B2/ja not_active Expired - Fee Related
- 2014-08-21 US US14/465,027 patent/US8999971B2/en not_active Expired - Fee Related
2015
- 2015-02-22 US US14/628,261 patent/US9278930B2/en not_active Expired - Fee Related
- 2015-04-16 US US14/688,216 patent/US9540326B2/en not_active Expired - Fee Related
- 2015-05-04 HR HRP20150473TT patent/HRP20150473T1/hr unknown
- 2015-07-13 IL IL239918A patent/IL239918A0/en unknown
- 2015-09-29 HK HK15109530.1A patent/HK1208806A1/en unknown
2016
- 2016-12-01 US US15/366,437 patent/US20170298019A1/en not_active Abandoned
2018
- 2018-02-20 US US15/900,447 patent/US10562854B2/en not_active Expired - Fee Related
2021
- 2021-12-16 US US17/553,578 patent/US20220185778A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ES2782999T3 (es)	2020-09-16
KR20140122283A (ko)	2014-10-17
RU2012123388A (ru)	2013-12-20
WO2011057115A1 (fr)	2011-05-12
US20110112055A1 (en)	2011-05-12
AU2010314973B9 (en)	2015-03-19
HUE026109T2 (en)	2016-05-30
PT2649998E (pt)	2015-04-21
CN102595896A (zh)	2012-07-18
PL2496236T4 (pl)	2015-11-30
AU2010314973A1 (en)	2012-06-21
US8883774B2 (en)	2014-11-11
JP2013508462A (ja)	2013-03-07
KR101613103B1 (ko)	2016-04-18
US9540326B2 (en)	2017-01-10
KR101483831B1 (ko)	2015-01-21
HK1169313A1 (en)	2013-01-25
MX2012005274A (es)	2012-06-19
ES2424122T3 (es)	2013-09-27
PL2649998T3 (pl)	2015-08-31
IL219610A0 (en)	2012-07-31
HK1208806A1 (en)	2016-03-18
NZ629733A (en)	2016-02-26
EP2496082A1 (fr)	2012-09-12
WO2011057121A1 (fr)	2011-05-12
RU2012123386A (ru)	2013-12-20
US20190055198A1 (en)	2019-02-21
RU2012123387A (ru)	2013-12-20
SI2496084T1 (sl)	2015-08-31
ES2533128T3 (es)	2015-04-07
MY160066A (en)	2017-02-15
IL219612A0 (en)	2012-07-31
EP2853265B1 (fr)	2017-07-26
EP2496082B1 (fr)	2016-10-12
JP2014221826A (ja)	2014-11-27
US20130158010A1 (en)	2013-06-20
HRP20150772T1 (hr)	2015-08-28
IL219612A (en)	2016-11-30
AU2010314976B2 (en)	2014-03-06
RU2518416C2 (ru)	2014-06-10
EP2496084A4 (fr)	2012-11-21
JP5599467B2 (ja)	2014-10-01
EP2952192A1 (fr)	2015-12-09
CN102638983A (zh)	2012-08-15
AU2010314982A1 (en)	2012-06-21
MY161880A (en)	2017-05-15
PH12012500789A1 (en)	2012-11-26
ZA201204104B (en)	2013-02-27
CN102612367A (zh)	2012-07-25
CA2774043C (fr)	2015-04-14
RU2521251C2 (ru)	2014-06-27
ES2644998T3 (es)	2017-12-01
EP2853265A1 (fr)	2015-04-01
EP2954899A1 (fr)	2015-12-16
KR20120079846A (ko)	2012-07-13
BR112012010762A2 (pt)	2018-03-20
KR20140095105A (ko)	2014-07-31
US20150157617A1 (en)	2015-06-11
NZ600396A (en)	2014-08-29
PL2496236T3 (pl)	2013-10-31
IN2012DN04949A (fr)	2015-09-25
US8309537B2 (en)	2012-11-13
JP2013508463A (ja)	2013-03-07
US20110111058A1 (en)	2011-05-12
EP2649998B1 (fr)	2015-03-04
BR112012010762B1 (pt)	2021-08-03
DK2496236T3 (da)	2013-07-08
EP2954899B1 (fr)	2020-01-08
PL2853265T3 (pl)	2018-01-31
US20150218098A1 (en)	2015-08-06
JP5627040B2 (ja)	2014-11-19
JP2014159427A (ja)	2014-09-04
EP2496236A1 (fr)	2012-09-12
MX365138B (es)	2019-05-24
US20110110961A1 (en)	2011-05-12
JP2013508464A (ja)	2013-03-07
EP2496236B1 (fr)	2013-05-01
RS54010B1 (sr)	2015-10-30
DK2496084T3 (en)	2015-06-29
IL239918A0 (en)	2015-08-31
KR20150116464A (ko)	2015-10-15
CA2774046A1 (fr)	2011-05-12
JP5591939B2 (ja)	2014-09-17
JP5961665B2 (ja)	2016-08-02
AU2010314973B2 (en)	2014-08-28
IN2012DN04950A (fr)	2015-09-25
KR101445946B1 (ko)	2014-09-29
KR101591701B1 (ko)	2016-02-05
US8536181B2 (en)	2013-09-17
PH12012500790A1 (en)	2012-11-26
NZ600405A (en)	2014-08-29
PT2496084E (pt)	2015-08-21
BR112012010759A2 (pt)	2015-10-06
PT2496236E (pt)	2013-07-08
AU2010314976A1 (en)	2012-06-21
DK2649998T3 (en)	2015-05-04
JP2014139206A (ja)	2014-07-31
IL219610A (en)	2015-07-30
WO2011057112A1 (fr)	2011-05-12
PH12012500788A1 (en)	2016-07-27
ES2541613T3 (es)	2015-07-22
HK1169275A1 (en)	2013-01-25
EP2496236A4 (fr)	2012-09-12
IL219611A (en)	2017-03-30
CA2774046C (fr)	2014-01-21
BR112012010759B1 (pt)	2021-12-28
KR20120088833A (ko)	2012-08-08
MX2012005275A (es)	2012-06-19
EP2649998A1 (fr)	2013-10-16
RU2518071C2 (ru)	2014-06-10
PL2496084T3 (pl)	2015-09-30
DK2853265T3 (da)	2017-11-06
RS54124B1 (sr)	2015-12-31
US20130158045A1 (en)	2013-06-20
PT2853265T (pt)	2017-11-07
US9278930B2 (en)	2016-03-08
EP3698794A1 (fr)	2020-08-26
CA2774043A1 (fr)	2011-05-12
US20170298019A1 (en)	2017-10-19
US9045495B2 (en)	2015-06-02
KR20120079844A (ko)	2012-07-13
SI2649998T1 (sl)	2015-06-30
US20220185778A1 (en)	2022-06-16
NZ600400A (en)	2014-09-26
HRP20130691T1 (en)	2013-10-11
IL219611A0 (en)	2012-07-31
SMT201300096B (it)	2013-11-08
CA2774039A1 (fr)	2011-05-12
US8778412B2 (en)	2014-07-15
US10562854B2 (en)	2020-02-18
KR20140048341A (ko)	2014-04-23
CN102612367B (zh)	2014-02-19
JP5865411B2 (ja)	2016-02-17
KR20150016414A (ko)	2015-02-11
NO2853265T3 (fr)	2017-12-23
CA2774046E (fr)	2011-05-12
MY163511A (en)	2017-09-15
BR112012010766A2 (pt)	2015-10-06
EP3603644A1 (fr)	2020-02-05
EP2496084B1 (fr)	2015-06-10
EP2496084A1 (fr)	2012-09-12
CN102638983B (zh)	2014-11-26
AU2010314982B2 (en)	2013-08-29
HRP20150473T1 (hr)	2015-06-05
US20140364419A1 (en)	2014-12-11
MX2012005273A (es)	2012-06-19
HK1190334A1 (en)	2014-07-04
CN102595896B (zh)	2016-02-17
US8999971B2 (en)	2015-04-07
RS52870B (sr)	2013-12-31
EP2496082A4 (fr)	2012-11-21
EP2952192B1 (fr)	2019-05-15

Publication	Publication Date	Title
IN2012DN04940A (fr)	2015-09-25
MX2013004491A (es)	2013-11-04	Boronatos como inhibidores de arginasa.
MY164731A (en)	2018-01-30	Compound
MX2012000709A (es)	2012-03-16	Inhibidores de pirrolopiridina de cinasas.
MY150697A (en)	2014-02-28	Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
EA201391720A1 (ru)	2014-04-30	Замещенные диоксопиперидинилфталимидные производные
IN2012DN02081A (fr)	2015-08-21
MX2013012979A (es)	2013-12-06	Piridina y derivados de pirazina.
IN2014DN08886A (fr)	2015-05-22
PH12015501576A1 (en)	2016-02-01	Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
EA201390085A1 (ru)	2013-06-28	Композиции ингибиторов киназ для лечения рака
MX2014002683A (es)	2014-04-14	Derivados de benzonitrilo como inhibidores de cinasa.
MX2009013341A (es)	2010-01-18	Derivados de 6-(pirrolopiridinil)-pirimidinil-2-amina.
MX2013004298A (es)	2013-07-05	Derivados de quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinasa.
MX2010003365A (es)	2010-04-30	Derivados de tiazol para el tratamiento de cancer.
TN2014000016A1 (en)	2015-07-01	4 - piperidinyl compounds for use as tankyrase inhibitors
MX2013004004A (es)	2013-04-24	Pirrolidinonas como inhibidores de metionina aminopeptidasa (metap-2).
MX2011011083A (es)	2011-11-04	Compuestos heterociclicos como inhibidores de mek.
UA83875C2 (ru)	2008-08-26	Производные хинолина для применения в качестве микобактериальных ингибиторов
UA105000C2 (uk)	2014-04-10	ГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ СТЕАРОЇЛ-СоА-ДЕСАТУРАЗИ
MX2014003376A (es)	2014-07-10	Derivados de acido benzoico como inhibidores eif4e.
MX342947B (es)	2016-10-18	Tratamiento de diabetes tipo 2.
MY169330A (en)	2019-03-21	Method for inhibition of deubiquitinating activity
MX2020007152A (es)	2020-12-10	Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y metodos de sintesis de los mismos.
MY152040A (en)	2014-08-15	Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments